Build a lasting personal brand

Viromed Medical AG Appoints Christian Strauch to Management Board as Founder Uwe Perbandt Steps Down

By Burstable Editorial Team•
Viromed Medical AG restructures its Management Board, appointing Christian Strauch to succeed founder Uwe Perbandt, positioning the cold plasma technology firm for its next growth phase.
Viromed Medical AG Appoints Christian Strauch to Management Board as Founder Uwe Perbandt Steps Down

Viromed Medical AG, a German medical technology company specializing in cold plasma technology for medical applications, is restructuring its Management Board as it enters a new phase of growth. The Supervisory Board has appointed Christian Strauch to the Management Board effective November 16, 2026, for a term running until October 31, 2029. Simultaneously, founder Uwe Perbandt has resigned from his position on the Management Board effective December 31, 2026, for personal reasons. The change was made by mutual agreement.

Dr. Thomas Gutschlag, Chairman of the Supervisory Board, commented: "The change on the Management Board takes place by mutual agreement with Uwe Perbandt. He shaped Viromed from the very beginning and, with tremendous commitment, developed the company into an internationally leading enterprise in the field of cold plasma technology. With the recently achieved market readiness of Viromed's technology, we now stand at the threshold of an exciting next growth phase. We are convinced that Christian Strauch, with his well-founded sales expertise, is the ideal candidate to help shape this phase successfully."

Perbandt, who will leave the board at the end of 2026, expressed confidence in his successor. "For many years, I built Viromed with great passion and a highly dedicated team, and I am very proud of what we have achieved together. With Christian Strauch, I am handing over responsibility to a highly experienced successor – my preferred candidate – and I leave the Management Board with a clear conscience."

Christian Strauch brings over twenty years of experience in building and scaling healthcare companies. He is currently Managing Director of pharmedix GmbH, a Viromed subsidiary. Strauch founded and grew the mail-order pharmacy apo-rot to 450 employees and annual revenue of up to EUR 100 million, later overseeing the sale of its mail-order division to the Zur Rose Group or DocMorris. He also led the integration of acquisitions for two DocMorris subsidiaries and restructured the group's procurement. Since 2020, he has been building the Vameda Group and founded two pharmaceutical wholesalers that were sold to an investor group in 2024. He also repositioned pharmedix GmbH as an omnichannel sales company, which Viromed acquired in 2024.

Viromed Medical AG has been listed on the stock exchange since October 2022 and focuses on the distribution of innovative cold plasma technology through its wholly owned subsidiary, Viromed Medical GmbH. The company serves a broad customer base in the DACH region and beyond. The leadership transition comes as Viromed's cold plasma technology has achieved market readiness, which the Supervisory Board sees as a catalyst for further expansion. Strauch's extensive sales and scaling expertise is expected to drive the company's next growth phase, potentially accelerating the adoption of cold plasma technology in medicine and strengthening Viromed's market position.

For more information, visit the company's website at www.viromed-medical-ag.de or view the original release on www.newmediawire.com.

Burstable Editorial Team

Burstable Editorial Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.